Literature DB >> 33299132

Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma.

Yang Liu1,2, Yoshifumi Baba2,3, Takatsugu Ishimoto2,4, Hiroyasu Tsutsuki5, Tianli Zhang5, Daichi Nomoto2, Kazuo Okadome2, Kensuke Yamamura2, Kazuto Harada2, Kojiro Eto2, Yukiharu Hiyoshi2, Masaaki Iwatsuki2, Yohei Nagai2, Shiro Iwagami2, Yuji Miyamoto2, Naoya Yoshida2, Yoshihiro Komohara6, Masaki Ohmuraya7, Xiaoming Wang8, Jaffer A Ajani9, Tomohiro Sawa5, Hideo Baba10,11.   

Abstract

BACKGROUND: Fusobacterium nucleatum (F. nucleatum) is a gut microbe implicated in gastrointestinal tumorigenesis. Predicting the chemotherapeutic response is critical to developing personalised therapeutic strategies for oesophageal cancer patients. The present study investigated the relationship between F. nucleatum and chemotherapeutic resistance in oesophageal squamous cell carcinoma (ESCC).
METHODS: We examined the relationship between F. nucleatum and chemotherapy response in 120 ESCC resected specimens and 30 pre-treatment biopsy specimens. In vitro studies using ESCC cell lines and co-culture assays further uncovered the mechanism underlying chemotherapeutic resistance.
RESULTS: ESCC patients with F. nucleatum infection displayed lesser chemotherapeutic response. The infiltration and subsistence of F. nucleatum in the ESCC cells were observed by transmission electron microscopy and laser scanning confocal microscopy. We also observed that F. nucleatum modulates the endogenous LC3 and ATG7 expression, as well as autophagosome formation to induce chemoresistance against 5-FU, CDDP, and Docetaxel. ATG7 knockdown resulted in reversal of F. nucleatum-induced chemoresistance. In addition, immunohistochemical studies confirmed the correlation between F. nucleatum infection and ATG7 expression in 284 ESCC specimens.
CONCLUSIONS: F. nucleatum confers chemoresistance to ESCC cells by modulating autophagy. These findings suggest that targeting F. nucleatum, during chemotherapy, could result in variable therapeutic outcomes for ESCC patients.

Entities:  

Year:  2020        PMID: 33299132      PMCID: PMC7921654          DOI: 10.1038/s41416-020-01198-5

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  42 in total

1.  Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma.

Authors:  Hiroki Hara; Makoto Tahara; Hiroyuki Daiko; Ken Kato; Hiroyasu Igaki; Shigenori Kadowaki; Yoichi Tanaka; Yasuo Hamamoto; Hisayuki Matsushita; Michitaka Nagase; Yoshinori Hosoya
Journal:  Cancer Sci       Date:  2013-10-18       Impact factor: 6.716

2.  Cancer statistics, 2014.

Authors:  Rebecca Siegel; Jiemin Ma; Zhaohui Zou; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-07       Impact factor: 508.702

3.  Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.

Authors:  Katrin M Sjoquist; Bryan H Burmeister; B Mark Smithers; John R Zalcberg; R John Simes; Andrew Barbour; Val Gebski
Journal:  Lancet Oncol       Date:  2011-06-16       Impact factor: 41.316

4.  Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.

Authors:  Toshiyasu Ojima; Mikihito Nakamori; Masaki Nakamura; Masahiro Katsuda; Keiji Hayata; Tomoya Kato; Junya Kitadani; Hirotaka Tabata; Akihiro Takeuchi; Makoto Iwahashi; Hiroki Yamaue
Journal:  Anticancer Res       Date:  2016-02       Impact factor: 2.480

5.  Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Authors:  Bertrand Routy; Emmanuelle Le Chatelier; Lisa Derosa; Connie P M Duong; Maryam Tidjani Alou; Romain Daillère; Aurélie Fluckiger; Meriem Messaoudene; Conrad Rauber; Maria P Roberti; Marine Fidelle; Caroline Flament; Vichnou Poirier-Colame; Paule Opolon; Christophe Klein; Kristina Iribarren; Laura Mondragón; Nicolas Jacquelot; Bo Qu; Gladys Ferrere; Céline Clémenson; Laura Mezquita; Jordi Remon Masip; Charles Naltet; Solenn Brosseau; Coureche Kaderbhai; Corentin Richard; Hira Rizvi; Florence Levenez; Nathalie Galleron; Benoit Quinquis; Nicolas Pons; Bernhard Ryffel; Véronique Minard-Colin; Patrick Gonin; Jean-Charles Soria; Eric Deutsch; Yohann Loriot; François Ghiringhelli; Gérard Zalcman; François Goldwasser; Bernard Escudier; Matthew D Hellmann; Alexander Eggermont; Didier Raoult; Laurence Albiges; Guido Kroemer; Laurence Zitvogel
Journal:  Science       Date:  2017-11-02       Impact factor: 47.728

6.  Esophageal and esophagogastric junction cancers, version 1.2015.

Authors:  Jaffer A Ajani; Thomas A D'Amico; Khaldoun Almhanna; David J Bentrem; Stephen Besh; Joseph Chao; Prajnan Das; Crystal Denlinger; Paul Fanta; Charles S Fuchs; Hans Gerdes; Robert E Glasgow; James A Hayman; Steven Hochwald; Wayne L Hofstetter; David H Ilson; Dawn Jaroszewski; Kory Jasperson; Rajesh N Keswani; Lawrence R Kleinberg; W Michael Korn; Stephen Leong; A Craig Lockhart; Mary F Mulcahy; Mark B Orringer; James A Posey; George A Poultsides; Aaron R Sasson; Walter J Scott; Vivian E Strong; Thomas K Varghese; Mary Kay Washington; Christopher G Willett; Cameron D Wright; Debra Zelman; Nicole McMillian; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2015-02       Impact factor: 11.908

7.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

Review 8.  Oesophageal carcinoma.

Authors:  Arjun Pennathur; Michael K Gibson; Blair A Jobe; James D Luketich
Journal:  Lancet       Date:  2013-02-02       Impact factor: 79.321

9.  Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.

Authors:  Ayelet Sivan; Leticia Corrales; Nathaniel Hubert; Jason B Williams; Keston Aquino-Michaels; Zachary M Earley; Franco W Benyamin; Yuk Man Lei; Bana Jabri; Maria-Luisa Alegre; Eugene B Chang; Thomas F Gajewski
Journal:  Science       Date:  2015-11-05       Impact factor: 47.728

Review 10.  Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies.

Authors:  Concetta Panebianco; Angelo Andriulli; Valerio Pazienza
Journal:  Microbiome       Date:  2018-05-22       Impact factor: 14.650

View more
  13 in total

Review 1.  Oral Microbiota Variation: A Risk Factor for Development and Poor Prognosis of Esophageal Cancer.

Authors:  Xiaobo Song; Ole K Greiner-Tollersrud; Huimin Zhou
Journal:  Dig Dis Sci       Date:  2021-09-09       Impact factor: 3.487

Review 2.  The role of gut microbiota in the development of colorectal cancer: a review.

Authors:  Navami Koyande; Madhusree Gangopadhyay; Shashidhar Thatikonda; Aravind Kumar Rengan
Journal:  Int J Colorectal Dis       Date:  2022-06-15       Impact factor: 2.796

Review 3.  Intratumor microbiome in cancer progression: current developments, challenges and future trends.

Authors:  Jinyan Liu; Yi Zhang
Journal:  Biomark Res       Date:  2022-05-31

Review 4.  Gut microbiome in gastrointestinal cancer: a friend or foe?

Authors:  Yang Liu; Yoshifumi Baba; Takatsugu Ishimoto; Xi Gu; Jun Zhang; Daichi Nomoto; Kazuo Okadome; Hideo Baba; Peng Qiu
Journal:  Int J Biol Sci       Date:  2022-06-21       Impact factor: 10.750

Review 5.  Fusobacterium nucleatum: a new player in regulation of cancer development and therapeutic response.

Authors:  Tengda Zhao; Xueping Wang; Liwu Fu; Ke Yang
Journal:  Cancer Drug Resist       Date:  2022-05-12

Review 6.  Potential influence of the microbiome environment in patients with biliary tract cancer and implications for therapy.

Authors:  Roseanna C Wheatley; Elaine Kilgour; Timothy Jacobs; Angela Lamarca; Richard A Hubner; Juan W Valle; Mairéad G McNamara
Journal:  Br J Cancer       Date:  2021-10-18       Impact factor: 9.075

Review 7.  3D Organoids: An Untapped Platform for Studying Host-Microbiome Interactions in Esophageal Cancers.

Authors:  Samuel Flashner; Kelley S Yan; Hiroshi Nakagawa
Journal:  Microorganisms       Date:  2021-10-20

Review 8.  Crosstalk between autophagy and microbiota in cancer progression.

Authors:  Yu Wang; Jiang Du; Xuemei Wu; Ahmed Abdelrehem; Yu Ren; Chao Liu; Xuan Zhou; Sinan Wang
Journal:  Mol Cancer       Date:  2021-12-11       Impact factor: 27.401

Review 9.  Fusobacterium nucleatum and Malignant Tumors of the Digestive Tract: A Mechanistic Overview.

Authors:  Yue Lai; Jun Mi; Qiang Feng
Journal:  Bioengineering (Basel)       Date:  2022-06-28

Review 10.  Fusobacterium nucleatum and Colorectal Cancer.

Authors:  Rongrong Li; Jilu Shen; Yuanhong Xu
Journal:  Infect Drug Resist       Date:  2022-03-17       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.